This acquired resistance to GC treatment was further confirmed in an experimental model for therapy-induced relapse in T-ALL patient-derived xenografts (PDXs).60 To do so, primary T-ALL bone marrow samples were transplanted in immunocompromised mice and were treated with repeated blocks of a 4-drug chemotherapy combination (vincristine, dexamethasone, L-asparaginase, and daunorubicin), which closely resembles the current ALL induction-therapy protocols. The gene discussed is ASPG; the disease is acute lymphoblastic leukemia.